Work

SP-012 Pembrolizumab in the first line treatment of recurrent and/or metastatic head and neck cancer

Year: 2019

Type: conference-abstract

Source: Radiotherapy and Oncology

DOI: 10.1016/s0167-8140(19)30178-1

Author: B. Burtness

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,000

OpenAlex ID: W2938951517

Cites:

Cited by:

Related to: 10